Brian M. Culley - 10 Mar 2025 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LCTX	Employee Stock Option (Right to Buy)	Award	$0	+2,300,000		$0.000000	2,300,000	10 Mar 2025	Common Shares	2,300,000	$0.5300	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	One quarter of the options shall vest on March 10, 2026, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.